Literature DB >> 9205056

Loss of imprinting of the insulin-like growth factor II gene in renal cell carcinoma.

N Nonomura1, K Nishimura, T Miki, N Kanno, Y Kojima, M Yokoyama, A Okuyama.   

Abstract

Loss of imprinting (LOI) has been implicated in the pathogenesis of embryonal malignancies as well as adult cancers. Insulin-like growth factor II (IGF2) gene is an imprinted gene, normally transcribed only from the paternal allele. We investigated allele-specific expression of the IGF2 gene in 22 cases of renal cell carcinoma (RCC), a common adult-onset renal tumor. Sixteen cases (72%) were informative for IGF2 gene expression, and 9 (56%) of these cases showed biallelic expression of the IGF2 gene. Additionally, in four cases with biallelic expression from which uninvolved kidney tissue was available, LOI of the IGF2 gene was also demonstrated in the normal tissue. All cases with LOI of IGF2 were low-grade and low-stage tumors. LOI of the IGF2 gene in RCC was not associated with overexpression of IGF2 mRNA, whereas IGF2 overexpression was frequently observed in high-stage tumors. These results suggest that LOI of IGF2 predisposes to low-grade and low-stage tumors, whereas IGF2 overexpression may have a role in RCC tumor progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9205056

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Genomic imprinting: implications for human disease.

Authors:  J G Falls; D J Pulford; A A Wylie; R L Jirtle
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

2.  Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.

Authors:  F Frasca; G Pandini; P Scalia; L Sciacca; R Mineo; A Costantino; I D Goldfine; A Belfiore; R Vigneri
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

Review 3.  Genetic background of adrenocortical tumor development.

Authors:  M Kjellman; C Larsson; M Bäckdahl
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

4.  In vitro lead exposure changes DNA methylation and expression of IGF2 and PEG1/MEST.

Authors:  Monica D Nye; Cathrine Hoyo; Susan K Murphy
Journal:  Toxicol In Vitro       Date:  2015-01-14       Impact factor: 3.500

5.  IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics.

Authors:  Biyun Qian; Dionyssios Katsaros; Lingeng Lu; Emilie Marion Canuto; Chiara Benedetto; Alicia Beeghly-Fadiel; Herbert Yu
Journal:  Oncol Rep       Date:  2011-01       Impact factor: 3.906

6.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

7.  IGF-II promoter methylation and ovarian cancer prognosis.

Authors:  A C Beeghly; D Katsaros; A L Wiley; I A Rigault de la Longrais; A T Prescott; H Chen; M Puopolo; T J Rutherford; H Yu
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-14       Impact factor: 4.553

8.  Decreased expression of p57(KIP2)mRNA in human bladder cancer.

Authors:  M Oya; W A Schulz
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

9.  H19 and IGF-2 allele-specific expression in hepatoblastoma.

Authors:  J A Ross; G A Radloff; S M Davies
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.